Teclistamab (Tecvayli®). HTA ID: 22064

Assessment Status NCPE Assessment Process Complete
HTA ID 22064
Drug Teclistamab
Brand Tecvayli®
Indication As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Assessment Process
Rapid review commissioned 20/09/2022
Rapid review completed 03/11/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of teclistamab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 29/11/2022
Pre-submission consultation with Applicant 24/01/2023
Full submission received from Applicant 18/05/2023
Preliminary review sent to Applicant 06/02/2024
NCPE assessment re-commenced 07/03/2024
Follow-up to preliminary review sent to Applicant 16/04/2024
NCPE assessment re-commenced 01/05/2024
Additional follow-up to Preliminary Review sent to Applicant 09/05/2024
NCPE assessment re-commenced 10/05/2024
Factual accuracy sent to Applicant 05/06/2024
NCPE assessment re-commenced 12/06/2024
NCPE assessment completed 04/07/2024
NCPE assessment outcome The NCPE recommends that teclistamab not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary

Plain English Summary